INDIA: GOVT PLEDGES PHARMA R&D BOOST

26 June 1994

In a new initiative to encourage pharmaceutical R&D, India's Minister for Chemicals and Fertilizers, Ram Lakham Singh Yadav, has said that soft loans from financial institutions can be made available to promote basic research in the industry. Saying the government "accords the highest priority to R&D," he added that the ministry would be taking further steps in this direction "very soon."

The Minister was speaking at a seminar organized by the Bulk Drug Manufacturers Association, at which Ministry Secretary K K Mathur asked the BDMA to send concrete proposals to the government outlining steps to be taken to promote research in the sector.

Mr Yadav said that the government's new drug policy, which has ceased to be an issue because of inordinate delays, is now at an "advanced stage." He said the delay has been due to sharp divisions within the industry, as different associations have sought different outcomes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight